Arch Biopartners Inc (ARCH) NPV

Sell:1.09 CADBuy:1.10 CAD0.02 CAD (1.83%)

Prices delayed by at least 15 minutes
Sell:1.09 CAD
Buy:1.10 CAD
Change:0.02 CAD (1.83%)
Prices delayed by at least 15 minutes
Sell:1.09 CAD
Buy:1.10 CAD
Change:0.02 CAD (1.83%)
Prices delayed by at least 15 minutes

Company Information

About this company

Arch Biopartners Inc. is a therapeutic biotech company developing novel drugs for acute and chronic kidney diseases. The Company is advancing an integrated pipeline that includes new treatments targeting inflammation and toxin-induced kidney injury. Its programs include a pre-clinical chronic kidney disease platform targeting interleukin-32 (IL-32), LSALT peptide, a dipeptidase-1 (DPEP1) inhibitor in Phase II for preventing cardiac surgery-associated acute kidney injury, and cilastatin, a repurposed drug in Phase II for preventing toxin-induced kidney damage. These assets represent distinct, mechanism-based approaches to treating and preventing common causes of kidney damage. Together, they target serious unmet needs in kidney care across both chronic and acute indications, affecting millions of patients worldwide. Its LSALT Peptide and cilastatin, are being developed to target kidney injury caused by inflammation or toxins respectively, which are both significant unmet medical needs.

Key people

Richard Muruve
Chief Executive Officer, President and Director
Andrew Bishop
Chief Financial Officer, Director
Claude Allary
Independent Director
Richard Rossman
Independent Director
Click to see more

Key facts

  • EPIC
    ARCH
  • Location
    Canada
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    CA03938C1041
  • Market cap
    CA$79.33m
  • Employees
    -
  • Shares in issue
    66.11m
  • Exchange
    TSX Venture Exchange
  • Index

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.